C M Vila, F A Moreno, M M Estébanez, G R Ares, G Villacampa, P Dashti, H S Oberoi, R Martin-Huertas, P Jares, L Alos, C Teixido, R Rull, M Sanchez, J Malvehy, E Carcelero, I Valduvieco, A A Fernandez
PURPOSE: We retrospectively analysed overall survival (OS) and potential predictive biomarkers of OS in patients with metastatic melanoma treated with ipilimumab plus nivolumab in a single institution. METHODS AND PATIENTS: Electronic medical records of patients with advanced melanoma receiving ≥ 1 dose of a combined ipilimumab plus nivolumab regimen between March 3, 2016 and March 7, 2020 in a single institution, were reviewed. OS was analysed using the Kaplan-Meier method...
February 2022: Clinical & Translational Oncology